INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Telix Pharmaceuticals Limited of Class Action Lawsuit and Upcoming Deadlines - TLX

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Telix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until January 9, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Telix securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         

[Click here for information about joining the class action]

On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company’s prostate cancer therapeutic candidates.” 

On this news, Telix’s American Depositary Receipt (“ADR”) price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. 

Then, on August 28, 2025, Telix issued a press release “announc[ing] that it has received a Complete Response Letter (CRL) from the United States (U.S.) Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), an investigational PET agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).”  Telix’s press release stated, in relevant part: “The CRL identifies deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package.  The FDA has requested additional data to establish comparability between the drug product used in the ZIRCON Phase 3 clinical trial and the scaled-up manufacturing process intended for commercial use.  Additionally, the FDA has documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission.” 

On this news, Telix’s ADR price fell $3.45 per ADR, or 18.75%, to close at $14.95 per ADR on August 28, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.